Currently, IL-6/IL-6R pathway inhibitors, such as tocilizumab, are predominantly utilised for their anti-inflammatory effects in autoimmune diseases, cytokine release syndrome, cancer-associated cachexia, and to enhance tolerance to immunotherapy [20,68]. This evidence concerns the gene IL6 and Cachexia.